| Revenue growth | Q4 revenue grew 10% YoY to INR 64 crores. |
|---|---|
| Margins | EBITDA margins stable at 16% for Q4; FY26 margin approx 21%. |
| Demand visibility | Strong demand in Gynaecology and Dermatology therapies. |
| Management confidence | High confidence in 1.5x IPM growth and accelerating FY27 momentum. |
Growth
FY26 Net Profit grew 19% before exceptions. Q4 PAT rose 31% YoY to ₹9cr with 14% margin.
Outlook
Targeting 1.5x Indian Pharma Market growth (approx. 12-15%); ₹40cr buyback and 200% dividend announced.
Risks
Macro risks and execution on new molecules; potential cost pressures from raw materials and packaging via CMOs.
Earnings Call filed with NSE, NSE: JAGSNPHARM. Summary written with AI assistance from the document.
Jagsonpal Pharmaceuticals Ltd: key numbers
- Share price
- ₹235.99
- Market cap
- ₹1,557 Cr
- Revenue (annual)
- ₹287.2 Cr
- Net profit (annual)
- ₹43.08 Cr
- P/E (TTM)
- 34.2×Sector 47.4×
- Promoter holding
- 69.05%+1.16% QoQ
- FII holding
- 2.30%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Jagsonpal Pharmaceuticals Ltd
All →Jagsonpal Pharmaceuticals Acquisition Worth ₹46.7 Cr
Jagsonpal Pharmaceuticals Ltd will acquire the Wellness Portfolio of Group Pharmaceuticals Ltd. The transaction involves a total consideration capped at ₹46.7 Crore.
- Value
- ₹46.70 Cr
Jagsonpal Pharmaceuticals Annual General Meeting
Jagsonpal Pharmaceuticals held its 47th Annual General Meeting on September 18, 2026. Shareholders transacted business including adoption of financial statements and director appointments.
Jagsonpal Pharmaceuticals Business Update
Jagsonpal Pharmaceuticals Ltd has filed its Business Responsibility and Sustainability Report for the financial year 2025-26. This report forms part of its annual report.
Jagsonpal Pharmaceuticals Annual General Meeting
Jagsonpal Pharmaceuticals Ltd has issued the notice for its 47th Annual General Meeting, scheduled for September 18, 2026, alongside the Annual Report for FY 2025-26.
Jagsonpal Pharmaceuticals Other Announcement
The company informed shareholders without registered email addresses of the web-link to access the 2025-26 Annual Report and AGM Notice, per Regulation 36(1)(b).
Jagsonpal Pharmaceuticals Employee Stock Options
Jagsonpal Pharmaceuticals Limited allotted 27,950 equity shares following the exercise of employee stock options. This increases the company's total paid-up share capital to Rs. 13.19 Crore.